Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment

Y. Fujiwara, Katsuyuki Hotta, M. di Maio, Katsuyuki Kiura, N. Takigawa, Masahiro Tabata, M. Tanimoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: Despite recent improvements in supportive care, treatment-related death (TRD) remains a serious problem for lung cancer patients undergoing systemic chemotherapy. However, few studies have formally assessed possible changes in the TRD rate over the past two decades. Patients and methods: We searched phase III trials to address the role of systemic treatment of advanced non-small-cell lung cancer (NSCLC). Time trend was assessed using linear regression analysis. Results: The overall incidence of TRD was calculated from 119 trials including 263 chemotherapy arms (46 477 patients), with information about the causes of deaths available for 197 arms (75%, 30 147 patients). Cisplatin-based regimens were the most frequently investigated. The crude TRD rate in the overall cohort of 119 trials was 1.26% and has been notably consistent over the investigated time (P = 0.762). The most common cause of death was febrile neutropenia, with no significant change in its incidence over the years (P = 0.139). In contrast, deaths due to renal toxicity decreased significantly (P = 0.042), whereas deaths due to pulmonary disorder increased significantly (P = 0.007). Among the pharmacological agents investigated, docetaxel (Taxotere) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were associated with relatively high rates of deaths from pulmonary disorders, but EGFR-TKIs were not associated with death from any other cause. Conclusions: Despite of potential confounders in our results, the overall TRD rate has remained low, but not negligible, in phase III trials for advanced NSCLC, over the past two decades. Notably, the incidence and pattern of TRD stratified by cause have changed considerably.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number2
DOIs
Publication statusPublished - 2011

Fingerprint

Non-Small Cell Lung Carcinoma
docetaxel
Cause of Death
Mortality
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Therapeutics
Incidence
Drug Therapy
Febrile Neutropenia
Lung
Cisplatin
Linear Models
Lung Neoplasms
Regression Analysis
Pharmacology
Kidney

Keywords

  • Chemotherapy
  • Lung cancer
  • Treatment-related death

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. / Fujiwara, Y.; Hotta, Katsuyuki; di Maio, M.; Kiura, Katsuyuki; Takigawa, N.; Tabata, Masahiro; Tanimoto, M.

In: Annals of Oncology, Vol. 22, No. 2, 2011, p. 376-382.

Research output: Contribution to journalArticle

@article{bf8dd279fcb2439f8433708200176749,
title = "Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment",
abstract = "Purpose: Despite recent improvements in supportive care, treatment-related death (TRD) remains a serious problem for lung cancer patients undergoing systemic chemotherapy. However, few studies have formally assessed possible changes in the TRD rate over the past two decades. Patients and methods: We searched phase III trials to address the role of systemic treatment of advanced non-small-cell lung cancer (NSCLC). Time trend was assessed using linear regression analysis. Results: The overall incidence of TRD was calculated from 119 trials including 263 chemotherapy arms (46 477 patients), with information about the causes of deaths available for 197 arms (75{\%}, 30 147 patients). Cisplatin-based regimens were the most frequently investigated. The crude TRD rate in the overall cohort of 119 trials was 1.26{\%} and has been notably consistent over the investigated time (P = 0.762). The most common cause of death was febrile neutropenia, with no significant change in its incidence over the years (P = 0.139). In contrast, deaths due to renal toxicity decreased significantly (P = 0.042), whereas deaths due to pulmonary disorder increased significantly (P = 0.007). Among the pharmacological agents investigated, docetaxel (Taxotere) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were associated with relatively high rates of deaths from pulmonary disorders, but EGFR-TKIs were not associated with death from any other cause. Conclusions: Despite of potential confounders in our results, the overall TRD rate has remained low, but not negligible, in phase III trials for advanced NSCLC, over the past two decades. Notably, the incidence and pattern of TRD stratified by cause have changed considerably.",
keywords = "Chemotherapy, Lung cancer, Treatment-related death",
author = "Y. Fujiwara and Katsuyuki Hotta and {di Maio}, M. and Katsuyuki Kiura and N. Takigawa and Masahiro Tabata and M. Tanimoto",
year = "2011",
doi = "10.1093/annonc/mdq360",
language = "English",
volume = "22",
pages = "376--382",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment

AU - Fujiwara, Y.

AU - Hotta, Katsuyuki

AU - di Maio, M.

AU - Kiura, Katsuyuki

AU - Takigawa, N.

AU - Tabata, Masahiro

AU - Tanimoto, M.

PY - 2011

Y1 - 2011

N2 - Purpose: Despite recent improvements in supportive care, treatment-related death (TRD) remains a serious problem for lung cancer patients undergoing systemic chemotherapy. However, few studies have formally assessed possible changes in the TRD rate over the past two decades. Patients and methods: We searched phase III trials to address the role of systemic treatment of advanced non-small-cell lung cancer (NSCLC). Time trend was assessed using linear regression analysis. Results: The overall incidence of TRD was calculated from 119 trials including 263 chemotherapy arms (46 477 patients), with information about the causes of deaths available for 197 arms (75%, 30 147 patients). Cisplatin-based regimens were the most frequently investigated. The crude TRD rate in the overall cohort of 119 trials was 1.26% and has been notably consistent over the investigated time (P = 0.762). The most common cause of death was febrile neutropenia, with no significant change in its incidence over the years (P = 0.139). In contrast, deaths due to renal toxicity decreased significantly (P = 0.042), whereas deaths due to pulmonary disorder increased significantly (P = 0.007). Among the pharmacological agents investigated, docetaxel (Taxotere) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were associated with relatively high rates of deaths from pulmonary disorders, but EGFR-TKIs were not associated with death from any other cause. Conclusions: Despite of potential confounders in our results, the overall TRD rate has remained low, but not negligible, in phase III trials for advanced NSCLC, over the past two decades. Notably, the incidence and pattern of TRD stratified by cause have changed considerably.

AB - Purpose: Despite recent improvements in supportive care, treatment-related death (TRD) remains a serious problem for lung cancer patients undergoing systemic chemotherapy. However, few studies have formally assessed possible changes in the TRD rate over the past two decades. Patients and methods: We searched phase III trials to address the role of systemic treatment of advanced non-small-cell lung cancer (NSCLC). Time trend was assessed using linear regression analysis. Results: The overall incidence of TRD was calculated from 119 trials including 263 chemotherapy arms (46 477 patients), with information about the causes of deaths available for 197 arms (75%, 30 147 patients). Cisplatin-based regimens were the most frequently investigated. The crude TRD rate in the overall cohort of 119 trials was 1.26% and has been notably consistent over the investigated time (P = 0.762). The most common cause of death was febrile neutropenia, with no significant change in its incidence over the years (P = 0.139). In contrast, deaths due to renal toxicity decreased significantly (P = 0.042), whereas deaths due to pulmonary disorder increased significantly (P = 0.007). Among the pharmacological agents investigated, docetaxel (Taxotere) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were associated with relatively high rates of deaths from pulmonary disorders, but EGFR-TKIs were not associated with death from any other cause. Conclusions: Despite of potential confounders in our results, the overall TRD rate has remained low, but not negligible, in phase III trials for advanced NSCLC, over the past two decades. Notably, the incidence and pattern of TRD stratified by cause have changed considerably.

KW - Chemotherapy

KW - Lung cancer

KW - Treatment-related death

UR - http://www.scopus.com/inward/record.url?scp=79251575000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251575000&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq360

DO - 10.1093/annonc/mdq360

M3 - Article

C2 - 20699278

AN - SCOPUS:79251575000

VL - 22

SP - 376

EP - 382

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -